Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiation Oncology | 12 | 2022 | 28 | 3.620 |
Why?
|
| Racism | 4 | 2023 | 42 | 1.550 |
Why?
|
| Breast Neoplasms | 7 | 2024 | 2753 | 1.130 |
Why?
|
| Minority Groups | 6 | 2018 | 248 | 1.080 |
Why?
|
| Mammography | 3 | 2024 | 132 | 1.070 |
Why?
|
| Brachytherapy | 3 | 2025 | 95 | 1.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2018 | 91 | 1.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 334 | 0.850 |
Why?
|
| Medicine | 2 | 2022 | 106 | 0.760 |
Why?
|
| Health Equity | 1 | 2023 | 73 | 0.750 |
Why?
|
| Diagnostic Imaging | 2 | 2014 | 315 | 0.720 |
Why?
|
| Physicians | 5 | 2020 | 640 | 0.700 |
Why?
|
| Sex Distribution | 4 | 2019 | 327 | 0.680 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2025 | 1312 | 0.680 |
Why?
|
| Education, Medical, Graduate | 4 | 2020 | 567 | 0.650 |
Why?
|
| Personnel Selection | 2 | 2018 | 69 | 0.650 |
Why?
|
| Mass Screening | 4 | 2024 | 833 | 0.640 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2025 | 261 | 0.630 |
Why?
|
| Endometrial Neoplasms | 2 | 2023 | 115 | 0.620 |
Why?
|
| Prostate-Specific Antigen | 2 | 2021 | 272 | 0.620 |
Why?
|
| Sexism | 3 | 2022 | 43 | 0.620 |
Why?
|
| Cultural Diversity | 5 | 2018 | 71 | 0.600 |
Why?
|
| Sexual Health | 1 | 2018 | 14 | 0.590 |
Why?
|
| Health Communication | 1 | 2018 | 31 | 0.590 |
Why?
|
| Genital Neoplasms, Female | 1 | 2018 | 45 | 0.580 |
Why?
|
| Faculty, Medical | 6 | 2020 | 281 | 0.560 |
Why?
|
| Organs at Risk | 1 | 2018 | 41 | 0.560 |
Why?
|
| Chemoradiotherapy | 5 | 2025 | 127 | 0.560 |
Why?
|
| Radiotherapy Dosage | 4 | 2024 | 233 | 0.560 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 1558 | 0.540 |
Why?
|
| Health Services Needs and Demand | 1 | 2018 | 177 | 0.540 |
Why?
|
| Prostatic Neoplasms | 3 | 2023 | 1599 | 0.520 |
Why?
|
| Survivors | 1 | 2018 | 358 | 0.500 |
Why?
|
| Mastectomy | 1 | 2015 | 81 | 0.470 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2024 | 285 | 0.470 |
Why?
|
| Vagina | 1 | 2016 | 206 | 0.430 |
Why?
|
| Health Personnel | 1 | 2018 | 549 | 0.420 |
Why?
|
| Neoadjuvant Therapy | 1 | 2015 | 404 | 0.400 |
Why?
|
| Sex Ratio | 1 | 2012 | 12 | 0.400 |
Why?
|
| United States | 19 | 2024 | 11761 | 0.390 |
Why?
|
| Female | 30 | 2025 | 71560 | 0.380 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2023 | 3869 | 0.370 |
Why?
|
| Head and Neck Neoplasms | 4 | 2020 | 634 | 0.360 |
Why?
|
| Humans | 43 | 2025 | 133529 | 0.360 |
Why?
|
| Neoplasms | 2 | 2023 | 2987 | 0.360 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 1697 | 0.350 |
Why?
|
| Veterans | 4 | 2022 | 1790 | 0.330 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 2088 | 0.320 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2024 | 786 | 0.310 |
Why?
|
| Radiation Oncologists | 2 | 2020 | 4 | 0.310 |
Why?
|
| Aged | 13 | 2025 | 21584 | 0.300 |
Why?
|
| Administrative Personnel | 2 | 2019 | 24 | 0.290 |
Why?
|
| Internship and Residency | 4 | 2022 | 1251 | 0.270 |
Why?
|
| Middle Aged | 12 | 2025 | 29081 | 0.260 |
Why?
|
| Male | 22 | 2024 | 65657 | 0.260 |
Why?
|
| Radiation Injuries | 2 | 2025 | 160 | 0.250 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2024 | 136 | 0.250 |
Why?
|
| Physicians, Women | 2 | 2017 | 52 | 0.250 |
Why?
|
| Hydronephrosis | 1 | 2025 | 38 | 0.230 |
Why?
|
| Positron-Emission Tomography | 2 | 2024 | 312 | 0.230 |
Why?
|
| Students, Medical | 2 | 2023 | 364 | 0.220 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2024 | 106 | 0.220 |
Why?
|
| Policy | 1 | 2023 | 37 | 0.210 |
Why?
|
| Early Detection of Cancer | 2 | 2024 | 414 | 0.200 |
Why?
|
| Public Health Surveillance | 2 | 2019 | 45 | 0.200 |
Why?
|
| Sexual Harassment | 1 | 2022 | 20 | 0.200 |
Why?
|
| Abortion, Induced | 1 | 2022 | 81 | 0.180 |
Why?
|
| Treatment Outcome | 4 | 2024 | 13101 | 0.180 |
Why?
|
| Breast | 1 | 2022 | 219 | 0.180 |
Why?
|
| Prognosis | 3 | 2020 | 5052 | 0.180 |
Why?
|
| Rectal Neoplasms | 1 | 2022 | 81 | 0.170 |
Why?
|
| Pharyngeal Muscles | 1 | 2020 | 11 | 0.170 |
Why?
|
| Blood Volume | 1 | 2020 | 78 | 0.170 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2021 | 99 | 0.160 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 658 | 0.150 |
Why?
|
| Deglutition Disorders | 1 | 2020 | 147 | 0.150 |
Why?
|
| Schools, Medical | 1 | 2019 | 124 | 0.150 |
Why?
|
| Orchiectomy | 1 | 2018 | 53 | 0.150 |
Why?
|
| Health Expenditures | 1 | 2019 | 117 | 0.150 |
Why?
|
| Computer Simulation | 1 | 2021 | 707 | 0.140 |
Why?
|
| Colon, Sigmoid | 1 | 2018 | 14 | 0.140 |
Why?
|
| Kidney | 1 | 2025 | 1382 | 0.140 |
Why?
|
| Prostatectomy | 1 | 2019 | 356 | 0.140 |
Why?
|
| Heart | 1 | 2022 | 692 | 0.140 |
Why?
|
| Sex Factors | 2 | 2019 | 1354 | 0.140 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2018 | 93 | 0.140 |
Why?
|
| Cost of Illness | 1 | 2019 | 277 | 0.140 |
Why?
|
| Employee Performance Appraisal | 1 | 2017 | 12 | 0.140 |
Why?
|
| Achievement | 1 | 2017 | 33 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 682 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2023 | 554 | 0.140 |
Why?
|
| Needs Assessment | 1 | 2018 | 181 | 0.140 |
Why?
|
| Radiation Dosage | 1 | 2018 | 146 | 0.130 |
Why?
|
| Rectum | 1 | 2018 | 114 | 0.130 |
Why?
|
| Models, Theoretical | 1 | 2019 | 394 | 0.130 |
Why?
|
| Patient Preference | 1 | 2018 | 135 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 336 | 0.130 |
Why?
|
| Women, Working | 1 | 2016 | 9 | 0.130 |
Why?
|
| Guideline Adherence | 1 | 2019 | 400 | 0.130 |
Why?
|
| Hematology | 1 | 2017 | 43 | 0.130 |
Why?
|
| Urinary Bladder | 1 | 2018 | 253 | 0.130 |
Why?
|
| Radiology, Interventional | 1 | 2016 | 35 | 0.130 |
Why?
|
| Medical Oncology | 2 | 2017 | 246 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2019 | 1268 | 0.130 |
Why?
|
| Quality Indicators, Health Care | 3 | 2022 | 230 | 0.120 |
Why?
|
| Specialization | 1 | 2016 | 81 | 0.120 |
Why?
|
| Quality of Life | 2 | 2023 | 2160 | 0.120 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 169 | 0.120 |
Why?
|
| Time Factors | 4 | 2020 | 6545 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 447 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 398 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 2190 | 0.100 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 965 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2022 | 5205 | 0.100 |
Why?
|
| Aged, 80 and over | 5 | 2025 | 7197 | 0.100 |
Why?
|
| Physics | 2 | 2022 | 8 | 0.100 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 739 | 0.100 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2011 | 20 | 0.090 |
Why?
|
| Incidence | 3 | 2025 | 3393 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2024 | 6586 | 0.090 |
Why?
|
| Nose Neoplasms | 1 | 2011 | 35 | 0.090 |
Why?
|
| Patient Selection | 1 | 2015 | 732 | 0.090 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 1375 | 0.090 |
Why?
|
| Surveys and Questionnaires | 4 | 2023 | 3990 | 0.090 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2011 | 107 | 0.090 |
Why?
|
| Registries | 2 | 2016 | 1591 | 0.080 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2023 | 213 | 0.080 |
Why?
|
| Adult | 6 | 2025 | 31787 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5453 | 0.080 |
Why?
|
| Disease Progression | 1 | 2015 | 2249 | 0.080 |
Why?
|
| Consensus | 2 | 2022 | 713 | 0.070 |
Why?
|
| Mentors | 2 | 2022 | 164 | 0.070 |
Why?
|
| Qualitative Research | 2 | 2023 | 659 | 0.070 |
Why?
|
| Linear Models | 2 | 2020 | 720 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2015 | 3725 | 0.060 |
Why?
|
| Career Choice | 2 | 2018 | 164 | 0.060 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2025 | 22 | 0.060 |
Why?
|
| Age Factors | 2 | 2024 | 2956 | 0.060 |
Why?
|
| Medical Overuse | 1 | 2024 | 26 | 0.050 |
Why?
|
| Carboplatin | 1 | 2024 | 86 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2024 | 143 | 0.050 |
Why?
|
| Social Identification | 1 | 2023 | 20 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2024 | 143 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2024 | 170 | 0.050 |
Why?
|
| Unemployment | 1 | 2023 | 23 | 0.050 |
Why?
|
| Cisplatin | 1 | 2025 | 285 | 0.050 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2023 | 35 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2024 | 188 | 0.050 |
Why?
|
| Developed Countries | 1 | 2022 | 42 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2024 | 499 | 0.040 |
Why?
|
| Taxoids | 1 | 2021 | 72 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2024 | 318 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2024 | 361 | 0.040 |
Why?
|
| Cause of Death | 1 | 2023 | 504 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2022 | 134 | 0.040 |
Why?
|
| Risk Factors | 1 | 2015 | 10970 | 0.040 |
Why?
|
| Deglutition | 1 | 2020 | 59 | 0.040 |
Why?
|
| Nitriles | 1 | 2021 | 155 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 79 | 0.040 |
Why?
|
| Androgen Antagonists | 1 | 2021 | 134 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2020 | 328 | 0.040 |
Why?
|
| Image Enhancement | 1 | 2020 | 174 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 398 | 0.040 |
Why?
|
| SEER Program | 1 | 2020 | 222 | 0.040 |
Why?
|
| Budgets | 1 | 2019 | 17 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2019 | 145 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2019 | 53 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2023 | 1463 | 0.040 |
Why?
|
| Enteral Nutrition | 1 | 2020 | 269 | 0.040 |
Why?
|
| Efficiency | 1 | 2019 | 70 | 0.040 |
Why?
|
| Employment | 1 | 2019 | 70 | 0.040 |
Why?
|
| Spouses | 1 | 2019 | 73 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2022 | 715 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 1053 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2019 | 596 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 1347 | 0.030 |
Why?
|
| Contrast Media | 1 | 2020 | 518 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1352 | 0.030 |
Why?
|
| Self Report | 1 | 2019 | 553 | 0.030 |
Why?
|
| Leadership | 1 | 2019 | 247 | 0.030 |
Why?
|
| Lung | 1 | 2024 | 1574 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 911 | 0.030 |
Why?
|
| Forecasting | 1 | 2018 | 376 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2018 | 429 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2025 | 1854 | 0.030 |
Why?
|
| Education | 1 | 2015 | 111 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2025 | 17579 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 2011 | 4 | 0.020 |
Why?
|
| Radiodermatitis | 1 | 2011 | 8 | 0.020 |
Why?
|
| Stomatitis | 1 | 2011 | 17 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2011 | 52 | 0.020 |
Why?
|
| Nasal Cavity | 1 | 2011 | 52 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2014 | 323 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 3417 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2011 | 362 | 0.020 |
Why?
|
| Pregnancy | 1 | 2022 | 7598 | 0.020 |
Why?
|
| Young Adult | 1 | 2011 | 9980 | 0.010 |
Why?
|
| Adolescent | 1 | 2011 | 20605 | 0.010 |
Why?
|
| Child | 1 | 2011 | 25888 | 0.010 |
Why?
|